MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

Non Driver NSCLC: The Immunotherapy Strategy

Non Driver NSCLC: The Immunotherapy Strategy

Luis E. Raez, MD, FACP, FCCP, FASCO

Other Driver Mutations: ROS-1, BRAF, MET and RET

Other Driver Mutations: ROS-1, BRAF, MET and RET

Erminia Massarelli, MD, PhD, MS

K-RAS Therapies in NSCLC

K-RAS Therapies in NSCLC

Julia Rotow, MD

ALK: First Line and Mechanism Of Resistance

ALK: First Line and Mechanism Of Resistance

Sai-Hong Ignatius Ou, MD, PhD

EGFR Exon 20 Insertions: Novel Agents

EGFR Exon 20 Insertions: Novel Agents

Millie Das, MD

What Is Next After Osimertinib Progression?

What Is Next After Osimertinib Progression?

Mark A. Socinski, MD

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

Jonathan Riess, MD, MS

Adjuvant Therapies in NSCLC

Adjuvant Therapies in NSCLC

Karen Kelly, MD

Optimal Surgical Approach in Early Stages NSCLC

Optimal Surgical Approach in Early Stages NSCLC

David H. Harpole, Jr., MD

Screening in Lung Cancer: Challenges and Obstacles

Screening in Lung Cancer: Challenges and Obstacles

Claudia Henschke, MD, PhD

Challenges in Lung Cancer Pathology: Biomarkers

Challenges in Lung Cancer Pathology: Biomarkers

Ignacio Wistuba, MD

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Cesar A. Santa-Maria, MD, MSCI

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Lajos Puzstai, MD, DPhil, FASCO

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Heather McArthur, MD, MPH

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Mariana Chavez-McGregor, MD, MSc, FASCO

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Mark Pegram, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Hope S. Rugo, MD, FASCO

Novel Advances for Thyroid Carcinoma and Thymoma

Novel Advances for Thyroid Carcinoma and Thymoma

Belisario Arango, MD

Soft Tissue and Osteosarcomas: Novel Advances in 2024

Soft Tissue and Osteosarcomas: Novel Advances in 2024

Jonathan Trent, MD, PhD

Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts

Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts

Eduardo Smith Singares, MD, FACS, FCCM

Lifestyle Modifications in Reducing Risk of Recurrence

Lifestyle Modifications in Reducing Risk of Recurrence

Adrienne M. Vazquez Guerra, MSN, ACNP-BC, AOCN®

End of Life Management: Oncologists’ Perspectives

End of Life Management: Oncologists’ Perspectives

Roberto Ochoa, MD

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

Tara Castellano, MD

Cervical and Uterine Cancer: Novel Advances in Personalized Medicine in 2024

Cervical and Uterine Cancer: Novel Advances in Personalized Medicine in 2024

Kathleen N. Moore, MD, MS

Melanoma: Novel Advances in Immunotherapy

Melanoma: Novel Advances in Immunotherapy

Sanjiv Agarwala, MD, FASCO

Squamous Cell Carcinoma of Head and Neck: Where Are We in 2024?

Squamous Cell Carcinoma of Head and Neck: Where Are We in 2024?

Marshall Posner, MD

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against)

Thomas Reske, MD, PhD

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor)

Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor)

Ahmed Zakari, MD

Colorectal Cancer: Novel Treatment Paradigms

Colorectal Cancer: Novel Treatment Paradigms

Heinz-Josef Lenz, MD